Survival outcomes of non‑definitive therapy for muscle‑invasive bladder cancer

Nishihara,Kiyoaki; Ueda,Kosuke; Kurose,Hirofumi; Ogasawara,Naoyuki; Hiroshige,Tasuku; Chikui,Katsuaki; Ejima,Kazuhisa; Uemura,Keiichiro; Nakiri,Makoto; Suekane,Shigetaka; Igawa,Tsukasa

doi:10.3892/ol.2022.13246

Survival outcomes of non‑definitive therapy for muscle‑invasive bladder cancer

Authors:
- Kiyoaki Nishihara
- Kosuke Ueda
- Hirofumi Kurose
- Naoyuki Ogasawara
- Tasuku Hiroshige
- Katsuaki Chikui
- Kazuhisa Ejima
- Keiichiro Uemura
- Makoto Nakiri
- Shigetaka Suekane
- Tsukasa Igawa
View Affiliations

Affiliations: Department of Urology, Kurume University School of Medicine, Kurume, Fukuoka 830‑0011, Japan
Published online on: February 17, 2022 https://doi.org/10.3892/ol.2022.13246
Article Number: 126

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

To analyze the risks and survival outcomes of non‑definitive therapy (nDT) for muscle‑invasive bladder cancer (MIBC), which may provide useful information for future treatment selection, the present study analyzed 124 patients who were diagnosed with MIBC (cT2‑4aN1‑2M0) and treated at Kurume University Hospital (Kurume, Japan) with definitive therapy (DT; including radical cystectomy and trimodal therapy) or nDT [transurethral resection of bladder tumor (TURBT) monotherapy or TURBT plus chemotherapy]. Differences in survival outcomes between the two groups were estimated using the Kaplan‑Meier method and analyzed using the log‑rank test. Cox proportional hazards regression models were used for multivariate analysis of each survival outcome. Of the 124 patients, 45% were treated with nDT, and among these, 50% were treated with TURBT monotherapy and 50% were treated with TURBT plus chemotherapy. Of the patients who chose definitive treatment, 69% were treated with radical cystectomy. The median age in the nDT group was 77 years, which was significantly higher than that in the DT group. Additionally, the proportion of patients with poor performance status, high Charlson comorbidity index and high neutrophil‑lymphocyte ratio values was significantly higher in the nDT group. nDT was associated with significantly reduced overall survival, cancer‑specific survival and progression‑free survival rates, and was a poor prognostic factor for all survival outcomes compared with DT. In conclusion, nDT was associated with a high cancer‑related mortality risk. The most appropriate treatment method should be discussed with the patients after providing them with sufficient information on the risks and benefits of each treatment method.

View Figures

View References

1	No authors listed. Cancer Statistics in Japan. Cancer information service, national cancer center; Japan: (Vital Statistics of Japan, Ministry of Health, Labour and Welfare). Available via DIALOG. https://ganjoho.jp/en/professional/statistics/table_download.htmlAugust 20–2021
2	Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmström PU, Choi W, Guo CC, Lotan Y and Kassouf W: Bladder cancer. Lancet. 388:2796–2810. 2016. View Article : Google Scholar : PubMed/NCBI
3	Witjes JA, Bruins HM, Cathomas R, Compérat EM, Cowan NC, Gakis G, Hernández V, Linares Espinós E, Lorch A, Neuzillet Y, et al: European association of urology guidelines on muscle-invasive and metastatic bladder cancer: Summary of the 2020 guidelines. Eur Urol. 79:82–104. 2021. View Article : Google Scholar : PubMed/NCBI
4	No authors listed. NCCN Guidelines. Bladder cancer. Available via DIALOG. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1417August 20–2021
5	Solsona E, Iborra I, Collado A, Rubio-Briones J, Casanova J and Calatrava A: Feasibility of radical transurethral resection as monotherapy for selected patients with muscle invasive bladder cancer. J Urol. 184:475–480. 2010. View Article : Google Scholar : PubMed/NCBI
6	Audenet F, Waingankar N, Ferket BS, Niglio SA, Marqueen KE, Sfakianos JP and Galsky MD: Effectiveness of transurethral resection plus systemic chemotherapy as definitive treatment for muscle invasive bladder cancer in population level data. J Urol. 200:996–1004. 2018. View Article : Google Scholar : PubMed/NCBI
7	Brierley JD, Gospodarowicz MK and Wittekind C: UICC TNM classification of malignant tumours. 8th edition. Wiley Blackwell; New Jersey, NY: 2016
8	Koie T, Ohyama C, Fujimoto H, Nishiyama H, Miyazaki J, Hinotsu S, Kikuchi E, Sakura M, Inokuchi J, Hara T, et al: Diversity in treatment modalities of Stage II/III urothelial cancer in Japan: Sub-analysis of the multi-institutional national database of the Japanese urological association. Jpn J Clin Oncol. 46:468–474. 2016. View Article : Google Scholar : PubMed/NCBI
9	Gray PJ, Fedewa SA, Shipley WU, Efstathiou JA, Lin CC, Zietman AL and Virgo KS: Use of potentially curative therapies for muscle-invasive bladder cancer in the United States: results from the national cancer data base. Eur Urol. 63:823–829. 2013. View Article : Google Scholar : PubMed/NCBI
10	Herr HW: Transurethral resection of muscle-invasive bladder cancer: 10-Year outcome. J Clin Oncol. 19:89–93. 2001. View Article : Google Scholar : PubMed/NCBI
11	Seisen T, Sun M, Lipsitz SR, Abdollah F, Leow JJ, Menon M, Preston MA, Harshman LC, Kibel AS, Nguyen PL, et al: Comparative effectiveness of trimodal therapy versus radical cystectomy for localized muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 72:483–487. 2017. View Article : Google Scholar : PubMed/NCBI
12	Fahmy O, Khairul-Asri MG, Schubert T, Renninger M, Malek R, Kübler H, Stenzl A and Gakis G: A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer. Urol Oncol. 36:43–53. 2018. View Article : Google Scholar : PubMed/NCBI
13	Mak KS, Smith AB, Eidelman A, Clayman R, Niemierko A, Cheng JS, Matthews J, Drumm MR, Nielsen ME, Feldman AS, et al: Quality of life in long-term survivors of muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys. 96:1028–1036. 2016. View Article : Google Scholar : PubMed/NCBI
14	Smith AB, Jaeger B, Pinheiro LC, Edwards LJ, Tan HJ, Nielsen ME and Reeve BB: Impact of bladder cancer on health-related quality of life. BJU Int. 121:549–557. 2018. View Article : Google Scholar : PubMed/NCBI
15	Cerruto MA, D'Elia C, Siracusano S, Gedeshi X, Mariotto A, Iafrate M, Niero M, Lonardi C, Bassi P, Belgrano E, et al: Systematic review and meta-analysis of non RCT's on health related quality of life after radical cystectomy using validated questionnaires: Better results with orthotopic neobladder versus ileal conduit. Eur J Surg Oncol. 42:343–360. 2016. View Article : Google Scholar : PubMed/NCBI
16	Clifford TG, Shah SH, Bazargani ST, Miranda G, Cai J, Wayne K, Djaladat H, Schuckman AK and Daneshmand S: Prospective evaluation of continence following radical cystectomy and orthotopic urinary diversion using a validated questionnaire. J Urol. 196:1685–1691. 2016. View Article : Google Scholar : PubMed/NCBI
17	Maffezzini M, Fontana V, Pacchetti A, Dotta F, Cerasuolo M, Chiappori D, Guano G, Mantica G and Terrone C: Age above 70 years and charlson comorbidity index higher than 3 are associated with reduced survival probabilities after radical cystectomy for bladder cancer. Data from a contemporary series of 334 consecutive patients. Arch Ital Urol Androl. 93:15–20. 2021. View Article : Google Scholar : PubMed/NCBI